Mastodawn

One infusion. One time. Possibly forever. A breakthrough gene-editing treatment just slashed LDL "bad" cholesterol by up to 62% — and the results are holding 18 months later. Published in the New England Journal of Medicine, the small study of 35 patients could reshape how we fight heart disease, which kills 800,000 Americans annually. No daily pills. No repeat treatments. Just one shot. Experts call it potentially "game-changing." Larger trials are next — but the early signs are extraordinary. The future of heart health may have just arrived. #HeartDisease #GeneTherapy #MedicalBreakthrough #Cholesterol #Health #Science #Medicine #NEJM #Innovation #Healthcare https://www.nytimes.com/2026/05/25/health/cholesterol-ldl-gene-therapy.html?unlocked_article_code=1.lVA.l-ru.p7FYphe9x4Tx&smid=nytcore-android-share

One-and-Done Heart Disease Prevention? Scientists Show It May Be Possible.

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point to something “curative,” one expert said.

The New York Times

Show thread

Faraiwe Apr 22

I don't think I can recall one such paper from #NEJM, before this.

https://www.nejm.org/doi/pdf/10.1056/NEJMe2029812

#TurdReich #COVID19

Ars Technica News Feb 5

Bad sleep made woman's eyelids so floppy they flipped inside out, got stuck https://arstechni.ca/KAR9 #obstructivesleepapnea #floppyeyelidsyndrome #eyelids #Health #sleep #NEJM #eye

Bad sleep made woman's eyelids so floppy they flipped inside out, got stuck

Never underestimate the value of a good night's sleep.

Ars Technica

Show thread

a6tole Oct 30, 2025

Finally, my warmest thanks to the CRICS-TriggerSep Scientific Board for their crucial role in designing and conducting this trial.

https://www.nejm.org/doi/full/10.1056/NEJMoa2502136

#EVERDAC #CriticalCare #ESICM2025 #NEJM #ICU #Research #CRICSTriggerSep

Deferring Arterial Catheterization in Critically Ill Patients with Shock | NEJM

In patients with shock, whether noninvasive blood-pressure monitoring is an effective alternative to the recommended use of an arterial catheter is uncertain. In this multicenter, open-label, nonin...

The New England Journal of Medicine

Science News Sep 30, 2025

Apixaban for Extended Treatment of Provoked Venous Thromboembolism. #NEJM "Low-intensity therapy with apixaban for 12 months resulted in a lower risk of symptomatic recurrent VTE than placebo, with a low risk of major bleeding." www.nejm.org/doi/full/10....

Science News Sep 21, 2025

Medical Imaging and Pediatric and Adolescent Hematologic Cancer Risk. #nejm "Our study suggests an association between exposure to radiation from medical imaging and a small but significantly increased risk of hematologic cancer among children and adolescents." www.nejm.org/doi/full/10....

Medical Imaging and Pediatric ...

Science News Sep 20, 2025

In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. #NEJM www.nejm.org/doi/full/10....

Orforglipron, an Oral Small-Mo...

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment | NEJM

Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, doubl...

The New England Journal of Medicine

Science News Sep 11, 2025

Marburg Virus Disease in Rwanda, 2024 — Public Health and Clinical Responses. #NEJM Open Access www.nejm.org/doi/full/10....

Science News Aug 26, 2025

In resectable lung cancer, neoadjuvant nivolumab plus chemotherapy improved 5-year overall survival, with no lung cancer deaths reported at 5 years in patients with a pathological complete response. #NEJM www.nejm.org/doi/full/10....